SCHEMBL3554675

SCHEMBL3554675

Cc1ccc(S(=O)(=O)Nc2ccccc2CCCc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 6/20 0.63
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
KCNA5 P22460 1/20 0.49
ALDH1A1 P00352 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 4/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TAS2R14 Q9NYV8 1/20 0.48
GFER P55789 1/20 0.48
USP2 O75604 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NOD2 Q9HC29 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
METAP2 P50579 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3555286 0.93 SLC16A3 (0.72) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3557081 0.92 SLC16A3 (0.66) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3563493 0.91 SLC16A3 (0.63) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3564319 0.91 SLC16A3 (0.63) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3561760 0.91 SLC16A3 (0.63) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3559581 0.91 SLC16A3 (0.63) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3561633 0.90 SLC16A3 (0.64) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3556182 0.89 SLC16A3 (0.68) SLC16A3HDAC3HDAC1NCOR2TAS2R14
SCHEMBL3556287 0.89 SLC16A3 (0.63) SLC16A3HDAC3HDAC1NCOR2ALDH1A1
SCHEMBL3558496 0.88 SLC16A3 (0.70) SLC16A3KCNA5LMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885HDAC3 3383/4885HDAC1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.